Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 7/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.64 |
| ▸ | CYP3A5 | P20815 | 6/20 | 0.64 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | RORC | P51449 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4558274 | 0.85 | CYP19A1 (0.65) | CYP19A1CYP3A4CYP3A5KCNA5RORC | |
| SCHEMBL7685830 | 0.84 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP3A5 | |
| SCHEMBL11632870 | 0.84 | CYP19A1 (0.54) | CYP19A1CYP3A4CYP3A5KCNA5CYP1A2 | |
| SCHEMBL27368720 | 0.82 | CYP3A4 (0.86) | CYP19A1CYP3A4CYP3A5KCNA5CYP1A2 | |
| SCHEMBL11631884 | 0.81 | CYP19A1 (0.51) | CYP19A1CYP3A4CYP3A5KCNA5CYP1A2 | |
| SCHEMBL9804417 | 0.81 | CYP19A1 (0.55) | CYP19A1CYP3A4CYP3A5RORC | |
| SCHEMBL913343 | 0.80 | CYP19A1 (0.79) | CYP19A1CYP3A4CYP3A5KCNA5 | |
| SCHEMBL4473850 | 0.80 | CYP19A1 (0.64) | CYP19A1CYP3A4CYP3A5RORC | |
| SCHEMBL19627972 | 0.79 | CYP19A1 (0.57) | CYP19A1CYP3A4CYP3A5KCNA5CYP1A2 | |
| SCHEMBL8986568 | 0.79 | CYP19A1 (0.61) | CYP19A1CYP3A4CYP3A5RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4116665-A | Method of regulating the growth of aquatic weeds with pyridine derivatives | ELI LILLY AND COMPANY (US) | 1978-09-26 | — | — | US | claimed |
| US-8017620-B2 | Dutpase inhibitors | MEDIVIR AB (SE) | 2011-09-13 | — | — | US | disclosed |
| US-20110021459-A1 | DUTPASE INHIBITORS | MEDIVIR AB (SE) | 2011-01-27 | — | — | US | disclosed |
| US-7795270-B2 | DUTPase inhibitors | MEDIVIR AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-20100075924-A1 | DUTPASE INHIBITORS | MEDIVIR AB (SE) | 2010-03-25 | — | — | US | disclosed |
| US-20100075924-A1 | DUTPASE INHIBITORS | MEDIVIR AB (SE) | 2010-03-25 | — | — | US | disclosed |
| US-7601702-B2 | Dutpase Inhibitors | MEDIVIR AB (SE) | 2009-10-13 | — | — | US | disclosed |
| US-7601702-B2 | Dutpase Inhibitors | MEDIVIR AB (SE) | 2009-10-13 | — | — | US | disclosed |
| US-7601702-B2 | Dutpase Inhibitors | MEDIVIR AB (SE) | 2009-10-13 | — | — | US | disclosed |
| US-7531573-B2 | potent, selective and safe inhibitors of the Ca2+-activated potassium channel | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531573-B2 | potent, selective and safe inhibitors of the Ca2+-activated potassium channel | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-05-12 | — | — | US | disclosed |
| US-20080312183-A1 | Dutpase Inhibitors | MEDIVIR AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080300216-A1 | Dutpase Inhibitors | MEDIVIR AB (SE) | 2008-12-04 | — | — | US | disclosed |
| US-20080300216-A1 | Dutpase Inhibitors | MEDIVIR AB (SE) | 2008-12-04 | — | — | US | disclosed |
| US-20080300216-A1 | Dutpase Inhibitors | MEDIVIR AB (SE) | 2008-12-04 | — | — | US | disclosed |
| US-4116665-A | Method of regulating the growth of aquatic weeds with pyridine derivatives | ELI LILLY AND COMPANY (US) | 1978-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300216-A1 | Dutpase Inhibitors | DUT, DHODH, POLR2H | CYP19A1 2254/4885CYP3A4 1028/4885CYP3A5 201/4885 |
| US-20080312183-A1 | Dutpase Inhibitors | DUT, DHODH, RNASEH1 | CYP19A1 2569/4885CYP3A4 1149/4885CYP3A5 283/4885 |
| US-20110021459-A1 | DUTPASE INHIBITORS | DUT, DHODH, NAT10 | CYP19A1 2730/4885CYP3A4 1010/4885CYP3A5 207/4885 |
| US-20100075924-A1 | DUTPASE INHIBITORS | DUT, DHODH, CCNO | CYP19A1 2491/4885CYP3A4 1235/4885CYP3A5 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.